GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Microba Life Sciences Ltd (ASX:MAP) » Definitions » Other Gross PPE

Microba Life Sciences (ASX:MAP) Other Gross PPE : A$0.00 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Microba Life Sciences Other Gross PPE?

Microba Life Sciences's Other Gross PPE for the quarter that ended in Dec. 2024 was A$0.00 Mil.

Microba Life Sciences's quarterly Other Gross PPE increased from Dec. 2023 (A$0.00 Mil) to Jun. 2024 (A$3.10 Mil) but then declined from Jun. 2024 (A$3.10 Mil) to Dec. 2024 (A$0.00 Mil).

Microba Life Sciences's annual Other Gross PPE increased from Jun. 2022 (A$1.70 Mil) to Jun. 2023 (A$2.07 Mil) and increased from Jun. 2023 (A$2.07 Mil) to Jun. 2024 (A$3.10 Mil).


Microba Life Sciences Other Gross PPE Historical Data

The historical data trend for Microba Life Sciences's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microba Life Sciences Other Gross PPE Chart

Microba Life Sciences Annual Data
Trend Jun22 Jun23 Jun24
Other Gross PPE
1.70 2.07 3.10

Microba Life Sciences Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Other Gross PPE Get a 7-Day Free Trial - 2.07 - 3.10 -

Microba Life Sciences Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


Microba Life Sciences Business Description

Traded in Other Exchanges
N/A
Address
324 Queen Street, Level 10, Brisbane, QLD, AUS, 4000
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are; Testing Services and Supplements which derives key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.

Microba Life Sciences Headlines

No Headlines